The 100m euro lifeline stabilizes liquidity and averts near-term disruption, but elevated leverage and delayed acquisition timing point to subdued margins and constrained offensive investment, risking share loss and valuation pressure until a credible product-led margin recovery is evidenced.
A 100m euro shareholder injection cures a covenant breach and stabilizes Valentino's near-term liquidity, but underscores weakening fundamentals and adds execution risk to Kering's turnaround sequencing. Delayed full acquisition to 2028 or later extends uncertainty on valuation and synergy capture, while EBITDA erosion and leverage constraints limit investment firepower in the next 2-3 quarters.